Diagnosis, classification and treatment of mucopolysaccharidosis type I

Bibliography

• Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
   PubMed Web of Science ®Google Scholar
• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle D, Beaudet A, Vogelstein B, et al. editors. The metabolic and molecular bases of inherited disease. McGraw-Hill; New York: 2014
   Google Scholar
• Toledo OMS, Dietrich CP. Tissue specific distribution of sulfated mucpolysaccharides in mammals. Biochim Biophys Acta 1977;498:114-22
   PubMed Web of Science ®Google Scholar
• Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319-28
   PubMed Web of Science ®Google Scholar
• Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 2004;15:433-44
   PubMed Web of Science ®Google Scholar
• Dickson PI, Hanson S, McEntee MF, et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab 2010;101:115-22
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Hamaguchi A, Nozaki I, et al. Cervical pachymeningeal hypertrophy as the initial and cardinal manifestation of mucopolysaccharidosis type I in monozygotic twins with a novel mutation in the alpha-L-iduronidase gene. J Neurol Sci 2011;302:121-5
   PubMedGoogle Scholar
• Aliabadi H, Reynolds R, Powers CJ, et al. Clinical outcome of cerebrospinal fluid shunting for communicating hydrocephalus in mucopolysaccharidoses I, II, and III: a retrospective analysis of 13 patients. Neurosurgery 2010;67:1476-81; discussion 1481–2
   PubMedGoogle Scholar
• Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A, et al. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in Hurler syndrome. Pediatr Res 2006;59:27-32
   PubMedGoogle Scholar
• Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg Am 1998;23:236-43
   PubMedGoogle Scholar
• Khanna G, Van Heest AE, Agel J, et al. Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007;39:331-4
   PubMed Web of Science ®Google Scholar
• Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006;51:1-17
   PubMed Web of Science ®Google Scholar
• McGlynn R, Dobrenis K, Walkley SU. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 2004;480:415-26
   PubMed Web of Science ®Google Scholar
• Wilkinson FL, Holley RJ, Langford-Smith KJ, et al. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One 2012;7:e35787
   PubMed Web of Science ®Google Scholar
• Tettamanti G, Bassi R, Viani P, Riboni L. Salvage pathways in glycosphingolipid metabolism. Biochimie 2003;85:423-37
   PubMed Web of Science ®Google Scholar
• Schwarzmann G, Sandhoff K. Metabolism and intracellular transport of glycosphyngolipids. Biochemistry 1990;29:10865-71
   PubMedGoogle Scholar
• Kint J, Dacremont G, Carton D, et al. Mucopolysaccharidosis: secondarily induced abnormal distribution of lysosomal isoenzymes. Science 1973;181:352-4
   PubMedGoogle Scholar
• Jos B, Avila L, Convit J. Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J 1975;152:57-64
   PubMedGoogle Scholar
• Platt FM, Boland B, van der Spoel AC. Lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol 2012;199:723-34
   PubMed Web of Science ®Google Scholar
• Settembre C, Fraldi A, Jahreiss L, et al. A block of autophagy in lysosomal storage disorders. Hum Mol Genet 2008;17:119-29
   PubMed Web of Science ®Google Scholar
• Simonaro CM, Ge Y, Eliyahu E, et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 2010;107:222-7
   PubMed Web of Science ®Google Scholar
• Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006;441:885-9
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741-52
   PubMed Web of Science ®Google Scholar
• Srinivas V, Bohensky J, Zahm AM, Shapiro IM. Autophagy in mineralizing tissues: microenvironmental perspectives. Cell Cycle 2009;8:391-3
   PubMed Web of Science ®Google Scholar
• Lord MS, Chuang CY, Melrose J, et al. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol 2014;35:112-22
   PubMed Web of Science ®Google Scholar
• Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002;12:117R-25R
   PubMed Web of Science ®Google Scholar
• Mizumoto S, Fongmoon D, Sugahara K. Interaction of chondroitin sulfate and dermatan sulfate from various biological sources with heparin-binding growth factors and cytokines. Glycoconj J 2013;30:619-32
   PubMedGoogle Scholar
• Pan C, Nelson MS, Reyes M, et al. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells. Blood 2005;106:1956-64
   PubMed Web of Science ®Google Scholar
• Simonaro CM, D’Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008;172:112-22
   PubMed Web of Science ®Google Scholar
• Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22
   PubMed Web of Science ®Google Scholar
• Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006;6:633-43
   PubMed Web of Science ®Google Scholar
• Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168:5233-9
   PubMed Web of Science ®Google Scholar
• Schuchman EH, Ge Y, Lai A, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 2013;8:e54459
   PubMed Web of Science ®Google Scholar
• Eliyahu E, Wolfson T, Ge Y, et al. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One 2011;6:e22447
   PubMed Web of Science ®Google Scholar
• Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis 2008;3:24
   PubMedGoogle Scholar
• Kingma SD, Langereis EJ, De Klerk CM, et al. An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life. Orphanet J Rare Dis 2013;8:99
   PubMed Web of Science ®Google Scholar
• Donaldson MD, Pennock CA, Berry PJ, et al. Hurler syndrome with cardiomyopathy in infancy. J Pediatr 1989;114:430-2
   PubMedGoogle Scholar
• Hopwood JJ, Vellodi A, Scott HS, et al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis 1993;16:1024-33
   PubMedGoogle Scholar
• Cleary M, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 1995;84:337-9
   PubMed Web of Science ®Google Scholar
• Colville G, Bax M. Early presentation in the mucopolysaccharide disorders. Child Care Health Dev 1995;22:31-6
   Google Scholar
• D’Aco K, Underhill L, Rangachari L, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr 2012;171:911-19
   PubMedGoogle Scholar
• Polgreen LE, Tolar J, Plog M, et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:1005-11
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997;76:92-9
   PubMed Web of Science ®Google Scholar
• Rozdzynska-Swiatowska A, Jurecka A, Cieslik J, Tylki-Szymańska A. Growth patterns in children with mucopolysaccharidosis. World J Pediatr 2014;1-6. [Epub ahead of print]
   Google Scholar
• Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007;120:e37-46
   PubMed Web of Science ®Google Scholar
• Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 2003;31:1105-17
   PubMed Web of Science ®Google Scholar
• White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology 2011;50(Suppl 5):v26-33
   Google Scholar
• Aldenhoven M, Sakkers RJB, Boelens J, et al. Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis 2009;68:1659-65
   PubMedGoogle Scholar
• Stoop E, Kruyt M, van der Linden MH, et al. Prevalence and development of orthopaedic symptoms in the Dutch Hurler patient population after haematopoietic stem cell transplantation. JIMD Rep 2013;9:17-29
   PubMedGoogle Scholar
• Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Jt Surg 1996;78:938-44
   Google Scholar
• Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995;18:413-29
   PubMed Web of Science ®Google Scholar
• Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr 2005;94:872-7
   PubMed Web of Science ®Google Scholar
• Illsinger S, Lücke T, Hartmann H, et al. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression. J Inherit Metab Dis 2009;32(Suppl 1):S321-5
   PubMedGoogle Scholar
• De Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 1989;35:1472-7
   PubMed Web of Science ®Google Scholar
• Dũng VC, Tomatsu S, Montaño AM, et al. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab 2013;110:129-38
   PubMed Web of Science ®Google Scholar
• Whiteman P. Prenatal diagnosis of mucopolysaccharidosis. Lancet 1976;301:1249
   Google Scholar
• Tomatsu S, Gutierrez MA, Ishimaru T, et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005;28:743-57
   PubMed Web of Science ®Google Scholar
• Fuller M, Rozaklis T, Ramsay SL, et al. Disease-specific markers for the mucopolysaccharidoses. Pediatr Res 2004;56:733-8
   PubMed Web of Science ®Google Scholar
• De Ruijter J, de Ru MH, Wagemans T, et al. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. Mol Genet Metab 2012;107:705-10
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Oguma T, et al. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J Inherit Metab Dis 2010;33:141-50
   PubMed Web of Science ®Google Scholar
• Oguma T, Tomatsu S, Montano AM, Okazaki O. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem 2007;368:79-86
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab 2013;110:42-53
   PubMed Web of Science ®Google Scholar
• De Ru MH, van der Tol L, van Vlies N, et al. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J Inherit Metab Dis 2013;36:247-55
   PubMedGoogle Scholar
• Tomatsu S, Montaño AM, Oguma T, et al. Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry. J Inherit Metab Dis 2010;33(Suppl 3):S35-42
   PubMedGoogle Scholar
• Auray-Blais C, Bhérer P, Gagnon R, et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab 2011;102:49-56
   PubMed Web of Science ®Google Scholar
• Chuang C-K, Lin H-Y, Wang T-J, et al. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis 2014;9:135
   PubMedGoogle Scholar
• Lawrence R, Brown JR, Al-Mafraji K, et al. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol 2012;8:197-204
   PubMedGoogle Scholar
• Lawrence R, Brown JR, Lorey F, et al. Glycan-based biomarkers for mucopolysaccharidoses. Mol Genet Metab 2014;111:73-83
   PubMedGoogle Scholar
• Aronovich EL, Pan D, Whitley CB. Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency. Am J Hum Genet 1996;58:75-85
   PubMed Web of Science ®Google Scholar
• Beesley CE, Meaney CA, Greenland G, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 2001;109:503-11
   PubMed Web of Science ®Google Scholar
• Venturi N, Rovelli A, Parini R, et al. Molecular analysis of 30 mucopolysaccharidosis type I patients: evaluation of the mutational spectrum in Italian population and identification of 13 novel mutations. Hum Mutat 2002;20:231
   PubMedGoogle Scholar
• Wang X, Zhang W, Shi H, et al. Mucopolysaccharidosis I mutations in Chinese patients: identification of 27 novel mutations and 6 cases involving prenatal diagnosis. Clin Genet 2012;81:443-52
   PubMed Web of Science ®Google Scholar
• Bertola F, Filocamo M, Casati G, et al. IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel alpha-L-iduronidase (IDUA) alleles. Hum Mutat 2011;32:E2189-210
   PubMed Web of Science ®Google Scholar
• Human Genome Mutation Database®. Available from: http://www.hgmd.cf.ac.uk/
   Google Scholar
• Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr 2013;163:498-503
   PubMed Web of Science ®Google Scholar
• Sista RS, Wang T, Wu N, et al. Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform. Clin Chim acta 2013;424:12-18
   PubMed Web of Science ®Google Scholar
• Campos D, Monaga M, González EC, et al. Optimization of enzymatic diagnosis for mucopolysaccharidosis I in dried blood spots on filter paper. Clin Biochem 2013;46:805-9
   PubMedGoogle Scholar
• Han M, Jun S-H, Song SH, et al. Use of tandem mass spectrometry for newborn screening of 6 lysosomal storage disorders in a Korean population. Korean J Lab Med 2011;31:250-6
   PubMedGoogle Scholar
• Gabrielli O, Clarke LA, Bruni S, Coppa G V. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010;125:e183-7
   PubMed Web of Science ®Google Scholar
• Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab 2014;111:63-72
   PubMed Web of Science ®Google Scholar
• Poe M, Chagnon S, Escolar M. Early treatment is associated with improved cognition in Hurler syndrome. Ann Neurol 2014;76:747-53
   PubMed Web of Science ®Google Scholar
• Laraway S, Breen C, Mercer J, et al. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol Genet Metab 2013;109:315-16
   PubMedGoogle Scholar
• Orchard PJ, Milla C, Braunlin E, et al. Pre-transplant risk factors affecting outcome in Hurler syndrome. Bone Marrow Transplant 2010;45:1239-46
   PubMed Web of Science ®Google Scholar
• De Ru MH, Bouwman MG, Wijburg FA, van Zwieten MCB. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening. Mol Genet Metab 2012;107:501-7
   PubMedGoogle Scholar
• Matern D, Oglesbee D, Tortorelli S. Newborn screening for lysosomal storage disorders and other neuronopathic conditions. Dev Disabil Res Rev 2013;17:247-53
   PubMedGoogle Scholar
• Lin S-P, Lin H-Y, Wang T-J, et al. A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 2013;8:147
   PubMedGoogle Scholar
• Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009;123:19-29
   PubMed Web of Science ®Google Scholar
• Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995;72:263-7
   PubMed Web of Science ®Google Scholar
• De Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 2011;6:55
   PubMed Web of Science ®Google Scholar
• Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med 2003;5:286-94
   PubMed Web of Science ®Google Scholar
• Bertola F, Filocamo M, Casati G, et al. IDUA mutational profiling of a cohort of 102 european patients with mucopolysaccharidosis type I: identification and characterization of 35 novel alpha -L-iduronidase (IDUA) alleles. Hum Mutat 2011;2210:2189-210
   Google Scholar
• Bunge S, Clements PR, Byers S, et al. Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta 1998;1407:249-56
   PubMed Web of Science ®Google Scholar
• Fuller M, Brooks DA, Evangelista M, et al. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 2005;84:18-24
   PubMed Web of Science ®Google Scholar
• Oussoren E, Keulemans J, van Diggelen OP, et al. Residual alpha-L-iduronidase activity in fibroblasts of mild to severe mucopolysaccharidosis type I patients. Mol Genet Metab 2013;109:377-81
   PubMedGoogle Scholar
• Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A, et al. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr 2009;98:743-9
   PubMed Web of Science ®Google Scholar
• De Ruijter J, Ijlst L, Kulik W, et al. Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease. J Inherit Metab Dis 2013;36:271-9
   PubMedGoogle Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162:570-2
   PubMed Web of Science ®Google Scholar
• Di Ferrante N, Nichols BL, Donnelly PV, et al. Induced degradation of glycosaminoglycans in Hurler’s and Hunter’s syndromes by plasma infusion. Proc Natl Acad Sci USA 1971;68:303-7
   PubMed Web of Science ®Google Scholar
• Kaplan A, Achord DT, Sly WS. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl Acad Sci USA 1977;74:2026-30
   PubMed Web of Science ®Google Scholar
• Hobbs J, Hugh-Jones H, Barret A, et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981;2:709-12
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013;121:3981-7
   PubMed Web of Science ®Google Scholar
• Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lyosomal and peroxisomal diseases. Cell Transplant 1995;4:385-92
   PubMed Web of Science ®Google Scholar
• Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 2000;97:10954-9
   PubMed Web of Science ®Google Scholar
• Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998;91:2601-8
   PubMed Web of Science ®Google Scholar
• Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87:4894-902
   PubMed Web of Science ®Google Scholar
• Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 1993;46:209-18
   PubMed Web of Science ®Google Scholar
• Grigull L, Sykora K-W, Tenger A, et al. Variable disease progression after successful stem cell transplantation: prospective follow-up investigations in eight patients with Hurler syndrome. Pediatr Transplant 2011;15:861-9
   PubMedGoogle Scholar
• Malone B, Whitley CB, Duall A, et al. Resolution of obstructive sleep apnea in Hurler syndrome after bone marrow transplantation. Int J Pediatr Otorhinolarynol 1988;15:23-31
   PubMedGoogle Scholar
• Field R, Buchanan J, Copplemans M, Aichroth P. Bone-marrow transplantation in Hurler’s syndrome. J Bone Joint Surg Br 1994;76:975-81
   PubMedGoogle Scholar
• Masterson E, Murphy P, O’Meara A, et al. Hip dysplasia in Hurler’s syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop 1996;16:731-3
   PubMedGoogle Scholar
• Kakkis ED, Muenzer J, Tiller G, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8
   PubMed Web of Science ®Google Scholar
• Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144:581-8
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Marucha J, Jurecka A, et al. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 2010;33:151-7
   PubMedGoogle Scholar
• Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;123:229-40
   PubMed Web of Science ®Google Scholar
• Braunlin EA, Berry JM, Whitley CB. Cardiac Findings After Enzyme Replacement Therapy for Mucopolysaccharidosis Type I. Am J Cardiol 2006;98:7-9
   Google Scholar
• Brands MM, Frohn-Mulder IM, Hagemans ML, et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis 2013;36:227-34
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli BZ, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab 2013;109:33-40
   PubMed Web of Science ®Google Scholar
• Langereis EJ, van Vlies N, Church HJ, et al. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol Genet Metab 2015;114(2):129-37
   PubMed Web of Science ®Google Scholar
• Dickson P, Peinovich M, Mcentee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 2008;118:2868-76
   PubMed Web of Science ®Google Scholar
• Węgrzyn G, Tylki-Szymańska A, Liberek A, et al. Rapid deterioration of a patient with Mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet A 2007;143A:1925-7
   PubMedGoogle Scholar
• Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis 2006;29:230-1
   PubMedGoogle Scholar
• Arn P, Whitley C, Wraith JE, et al. High rate of postoperative mortality in patients with mucopolysaccharidosis I: findings from the MPS I Registry. J Pediatr Surg 2012;47:477-84
   PubMed Web of Science ®Google Scholar
• Arn P, Wraith JE, Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J Pediatr 2009;154:859-64.e3
   PubMedGoogle Scholar
• Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007;90:171-80
   PubMed Web of Science ®Google Scholar
• Brien AO, Bompadre V, Hale S, White KK. Musculoskeletal function in patients with mucopolysaccharidosis using the pediatric outcomes data collection instrument. J Pediatr Orthop 2014;34:650-4
   PubMedGoogle Scholar
• Thawrani D, Walker K, Polgreen L, et al. Hip dysplasia in patients with Hurler syndrome (mucopolysaccharidosis type 1H). J Pediatr Orthop 2013;33(6):635-43
   PubMedGoogle Scholar
• Taylor C, Brady P, O’Meara A, et al. Mobility in Hurler syndrome. J Pediatr Orthop 2008;28:163-8
   PubMedGoogle Scholar
• Langereis EJ, Borgo A, Crushell E, et al. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis 2013;8:155
   PubMedGoogle Scholar
• Yasin MN, Sacho R, Oxborrow NJ, et al. Thoracolumbar kyphosis in treated mucopolysaccharidosis 1 (Hurler syndrome). Spine (Phila. Pa. 1976) 2014;39:381-7
   PubMedGoogle Scholar
• Abelin Genevois K, Garin C, Solla F, et al. Surgical management of thoracolumbar kyphosis in mucopolysaccharidosis type 1 in a reference center. J Inherit Metab Dis 2014;37:69-78
   PubMedGoogle Scholar
• Miebach E, Church H, Cooper A, et al. The craniocervical junction following successful haematopoietic stem cell transplantation for mucopolysaccharidosis type I H (Hurler syndrome). J Inherit Metab Dis 2011;34:755-61
   PubMedGoogle Scholar
• Boor R, Miebach E, Brühl K, Beck M. Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses. Neuropediatrics 2000;31:122-7
   PubMedGoogle Scholar
• Charrow J, Alden TD, Breathnach CA, et al. Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in patients with Morquio syndrome. Mol Genet Metab 2015;114:11-18
   PubMed Web of Science ®Google Scholar
• Tong C, Chen J, Douglas Cochrane D. Spinal cord infarction remote from maximal compression in a patient with Morquio syndrome. J Neurosurg Pediatr 2012;9:608-12
   PubMedGoogle Scholar
• Frawley G, Fuenzalida D, Donath S, et al. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Paediatr Anaesth 2012;22:737-44
   PubMedGoogle Scholar
• Arn P, Bruce IA, Wraith JE, et al. Airway-related symptoms and surgeries in patients with mucopolysaccharidosis I. Ann Otol Rhinol Laryngol 2015;124(3):198-205. 10.1177/0003489414550154
   PubMedGoogle Scholar
• Belani KG, Krivit W, Carpenter BL, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993;28:403-10
   PubMedGoogle Scholar
• Megens JH, de Wit M, van Hasselt PM, et al. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. Paediatr Anaesth 2014;24:521-7
   PubMedGoogle Scholar
• Kirkpatrick K, Ellwood J, Walker RW. Mucopolysaccharidosis type I (Hurler syndrome) and anesthesia: the impact of bone marrow transplantation, enzyme replacement therapy, and fiberoptic intubation on airway management. Paediatr Anaesth 2012;22:745-51
   PubMedGoogle Scholar
• Walker RW, Colovic V, Robinson D, Dearlove O. Postobstructive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paediatr Anaesth 2003;13:441-7
   PubMedGoogle Scholar
• Pastores GM. Laronidase (Aldurazyme®): enzyme replacement therapy for mucopolysaccharidosis type I. Expert Opin Biol Ther 2008;8:1003-9
   PubMed Web of Science ®Google Scholar
• Dierenfeld A, McEntee M, Vogler C, et al. Replacing the enzyme a-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2011;2:1-18
   Google Scholar
• Kakkis ED, Schuchman E, He X, et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001;72:199-208
   PubMed Web of Science ®Google Scholar
• Kakkis ED, McEntee MF, Schmidtchen A, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996;58:156-67
   PubMedGoogle Scholar
• Breider MA, Shull RM, Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am J Pathol 1989;134:677-92
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Rocha V, Aldenhoven M, et al. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol blood marrow Transplant 2009;15:618-25
   PubMed Web of Science ®Google Scholar
• Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 2013;162:375-80.e1
   PubMed Web of Science ®Google Scholar
• Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004;83:163-74
   PubMed Web of Science ®Google Scholar
• Extension study of intrathecal enzyme replacement therapy for MPS I. Available from: https://clinicaltrials.gov/ct2/show/NCT00786968?term=aldurazyme&rank=12
   Google Scholar
• Wang RY, Aminian A, McEntee MF, et al. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I. Mol Genet Metab 2014;112:286-93
   PubMedGoogle Scholar
• Barbier AJ, Bielefeld B, Whiteman DA, et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab 2013;110:303-10
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33
   PubMed Web of Science ®Google Scholar
• Schweighardt B, Tompkins T, Lau K, et al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial. Clin Ther 2014. [ [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Rombach SM, Aerts JM, Poorthuis BJ, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 2012;7:e47805
   PubMed Web of Science ®Google Scholar
• Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012;14:135-42
   PubMed Web of Science ®Google Scholar
• Banugaria SG, Prater SN, Ng Y-K, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011;13:729-36
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene 2013;525:174-81
   PubMed Web of Science ®Google Scholar
• Bigger BW, Wynn RF. Novel approaches and mechanisms in hematopoietic stem cell gene therapy. Discov Med 2014;94:207-15
   Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158
   PubMed Web of Science ®Google Scholar
• Cartier N, Hacein-bey-abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326:818-24
   PubMed Web of Science ®Google Scholar
• Wang D, El-Amouri SS, Dai M, et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci USA 2013;110:2999-3004
   PubMed Web of Science ®Google Scholar
• Boado RJ, Hui EK-W, Lu JZ, et al. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm 2011;8:1342-50
   PubMed Web of Science ®Google Scholar
• Kamei M, Kasperski K, Fuller M, et al. Aminoglycoside-induced premature stop codon read-through of mucopolysaccharidosis type I patient Q70X and W402X mutation in cultured cells. JIMD Rep 2014;13:139-47
   PubMedGoogle Scholar
• Polgreen LE, Thomas W, Orchard PJ, et al. Effect of recombinant human growth hormone on changes in height, bonemineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol Genet Metab 2014;111:101-6
   PubMed Web of Science ®Google Scholar
• De Ru MH, Teunissen QG, van der Lee JH, et al. Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure. Orphanet J Rare Dis 2012;7:22
   PubMedGoogle Scholar
• Wang RY, Bodamer OA, Watson MS, Wilcox WR. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 2011;13:457-84
   PubMed Web of Science ®Google Scholar
• MPS I Registry. Available from: www.mpsiregistry.com
   Google Scholar
• Church H, Tylee K, Cooper A, et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant 2007;39:207-10
   PubMedGoogle Scholar
• Clarke LA, Hemmelgarn H, Colobong K, et al. Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients. J Inherit Metab Dis 2012;35:355-62
   PubMed Web of Science ®Google Scholar